The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)

Ruhr University of Bochum600 enrolled

Overview

Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.

The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients compared to standard treatment without platelet function testing.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Coronary Artery Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * coronary stent implantation Exclusion Criteria: * no consent

Locations (1)

Cardiovascular Center, Ruhr-University Bochum

Bochum, North Rhine-Westphalia, Germany

Outcomes

Primary Outcomes

Adverse cardiac events (MACE: mortality,rehospitalisation,myocardial infarction)

MACE-rate

Time frame: Follow up for up to 12 months (retrospective analysis)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.